中链甘油三胺在阿尔茨海默病小鼠模型中改善认知和系统代谢
Paule E H M'Bra1,2,3, Laura K Hamilton4, Gaël Moquin-Beaudry4
1Research Center on Aging, CIUSSS de l'Estrie-CHUS, J1H 2J7, Sherbrooke, Canada.
Brain : a journal of neurology
|August 12, 2025
概括
中链甘油三 (MCT) 补充剂改善了阿尔茨海默病 (AD) 鼠标的认知和新陈代谢,而不会增加. 这表明MCT通过与性饮食不同的机制为AD提供了好处.
科学领域:
- 神经科学是一个神经科学.
- 代谢科学 代谢科学
- 饮食干预 饮食干预
背景情况:
- 包括饮食在内的生活方式干预可以减轻痴呆风险.
- 中链甘油三 (MCT) 在阿尔茨海默病 (AD) 方面表现有前途,可能是通过生产.
- 在AD中MCT益处的机制需要进一步阐明.
研究的目的:
- 在AD小鼠模型中,研究MCT补充剂对抗基因饮食 (KD) 的大脑和全身影响.
- 为了比较由MCT和KD引起的分子和生理变化.
- 了解在AD中MCT和KD干预的不同机制.
主要方法:
- 在3xTg-AD和5xFAD小鼠模型中,对照饮食,MCT补充饮食和KD的比较.
- 认知功能 (空间学习和记忆) 和海马神经元结构的评估.
- 系统代谢参数,肝脏基因表达和脂质代谢的分析.
主要成果:
- 在AD小鼠中,MCT和KD都改善了空间记忆和海马体树突脊柱密度.
- 在AD小鼠中,MCT增强了外周胰岛素反应,而KD加剧了AD小鼠的代谢功能障碍.
- 观察到明显的肝适应:MCT下调的胆固醇基因,KD诱导的炎症和脂质消耗.
结论:
- 在AD模型中,MCT补充改善了认知和全身新陈代谢,而不依赖升.
- MCT和KD对全身新陈代谢和肝脏基因表达有不同的影响.
- MCT为AD提供了一个潜在的治疗策略,具有独特的代谢益处.
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206
01:26Alzheimer's Disease: Overview
668
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
668
01:22Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261